drugset
drugset / Trial / NCT03556007

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

NCT03556007 ↗

Phase 1 Completed 48 enrolled Nektar Therapeutics Eli Lilly and Company · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in participants with SLE. The study will last about 79 days for each participant.

Timeline

Start
2018-04-18
Primary completion
2019-08-29
Completion
2019-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Rezpegaldesleukin Protein / enzyme biologic 3 ug/kg Subcutaneous
Subject Rezpegaldesleukin Protein / enzyme biologic 6 ug/kg Subcutaneous
Subject Rezpegaldesleukin Protein / enzyme biologic 12 ug/kg Subcutaneous
Subject Rezpegaldesleukin Protein / enzyme biologic 24 ug/kg Subcutaneous

Indications

systemic lupus erythematosus